FibroBiologics (FibroBiologics) Short-Term Capital Lease Obligation : $0.37 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Short-Term Capital Lease Obligation?

FibroBiologics's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.37 Mil.

FibroBiologics's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($0.35 Mil) to Dec. 2023 ($0.36 Mil) and increased from Dec. 2023 ($0.36 Mil) to Mar. 2024 ($0.37 Mil).

FibroBiologics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.33 Mil) and increased from Dec. 2022 ($0.33 Mil) to Dec. 2023 ($0.36 Mil).

FibroBiologics Short-Term Capital Lease Obligation Historical Data

The historical data trend for FibroBiologics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Short-Term Capital Lease Obligation Chart

FibroBiologics Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.33

0.36

FibroBiologics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial				-	0.34	0.35	0.36	0.37

FibroBiologics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

FibroBiologics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of FibroBiologics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

FibroBiologics (FibroBiologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SG0:Germany

Address

455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598

Website

https://www.fibrobiologics.com

FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines

From GuruFocus

FibroBiologics Announces Three United States Patents for Fibroblast Technology

By PRNewswire • 02-12-2024

FibroBiologics Announces Three Japanese Patents on Fibroblast Technology

By PRNewswire • 02-12-2024